Symposium on clinical aspects in hepatitis virus infection. 4. Topics of type C chronic liver disease.
Hayashi
N
N
The Department of Molecular Therapeutics, Osaka University School of Medicine.
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology / Q000209:etiology; D003713:Dendritic Cells / Q000276:immunology / Q000473:pathology; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D018664:Interleukin-12 / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology; D008113:Liver Neoplasms / Q000453:epidemiology / Q000209:etiology; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology
D000998:Antiviral Agents; D007376:Interleukin-2; D018664:Interleukin-12; D007372:Interferons